Genetic features may be the best indicator of responsiveness to blinatumomab, according to Australian clinicians who report which children with relapsed-refractory paediatric ALL respond to the bi-specific T-cell engager (BiTE) in the real-world setting. Their review of 24 cases outside clinical trials found 38% of patients were MRD-negative after blinatumomab – indicating a complete MRD ...
Aussie kids with relapsed/refractory ALL show 58% overall MRD response to blinatumomab
By Mardi Chapman
22 Mar 2021